Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region
- Pfizer, Johnson & Johnson (Janssen Pharmaceuticals), Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape Pfizer, Johnson & Johnson (Janssen Pharmaceuticals), Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape
- 01/08/2025
|
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco
- The Keynote Address, entitled " Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD ," will be presented at 10:30AM PT on Sunday January 12th, 2025 Prof. David Feifel MD PHD, designated Chief Medical Innovation Officer of HOPE and Founder of the Kadima Neuropsychiatry Institute, is an international thought leader in the interventional psychiatry space NRx Pharmaceuticals recently initiated filing of its NDA for NRX-100 (IV ketamine) for the treatment of suicidal depression Recent announcement of Kadima Neuropsychiatry Institute and Dura Medical as planned cornerstone acquisitions for HOPE Therapeutic's international network of interventional psychiatry clinics $27 Million in anticipated funding for HOPE Clinic acquisitions and pharmaceutical operations under a binding Term Sheet with an Institutional Investor MIAMI , Jan. 7, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced that Jonathan Javitt MD MPH, Founder and CEO of NRx and Co-CEO of HOPE, and Prof.
- 01/07/2025
|
Best Momentum Stocks to Buy for January 6th
- NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.
- 01/06/2025
|
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
- Anticipated c apital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations. Purchase of $25 m illion in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions.
- 01/06/2025
|
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics
- Dura Medical, with initial clinics in Naples and Fort Myers, to anchor the HOPE network in Florida Delivers a full range of precision psychiatry services, including Ketamine and Transcranial Magnetic Stimulation (TMS), to veteran and civilian residents of Florida Stephen Durand, founder of Dura, to serve as Director of Clinic Growth for HOPE in Florida Acquisition expected to be immediately accretive to revenue and EBITDA for NRx MIAMI , Jan. 6, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced the planned acquisition of Dura Medical (Dura), under a non-binding Letter of Intent. Dura is expected to be the first Florida acquisition for HOPE and serve as a cornerstone for the Southeastern States.
- 01/06/2025
|
New Strong Buy Stocks for January 6th
- ALK, AHT, NRXP, PDEX and EGAN have been added to the Zacks Rank #1 (Strong Buy) List on January 6, 2024.
- 01/06/2025
|
Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics
- Kadima Neuropsychiatry Institute in La Jolla, CA to serve as flagship for an international network of clinics dedicated to treating depression and PTSD Kadima's founder, David Feifel, MD, PhD, Professor Emeritus of Psychiatry at University of California San Diego, a pioneer in advanced interventional treatments for neuropsychiatric conditions such as depression and PTSD, to join Hope as Chief Medical Innovation Officer Kadima is a leading investigative site for CNS and psychedelic research, and has served as the lead site in nearly all major clinical trials in this area Acquisition expected to be immediately accretive to revenue and EBITDA for NRx MIAMI , Jan. 2, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced the planned acquisition of the Kadima Neuropsychiatry Institute (Kadima) of La Jolla, CA, per the previously announced Letter of Intent, for the HOPE network. Kadima is expected to serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and PTSD.
- 01/02/2025
|
Best Momentum Stocks to Buy for December 30th
- CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.
- 12/30/2024
|
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
- Aiming to be the first FDA-approved medication to treat suicidal depression Designed to help address the needs of the more than 13 million Americans who seriously consider suicide each year (CDC) Completion of NDA filing expected in the first quarter of 2025 Company to participate in 1x1 meetings in San Francisco during the Annual J.P. Morgan Healthcare Conference on January 13-16, 2025, in San Francisco, CA.
- 12/30/2024
|
New Strong Buy Stocks for December 30th
- CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024.
- 12/30/2024
|
New Strong Buy Stocks for December 26th
- EGAN,ACMR, AVO, BB and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 26, 2024.
- 12/26/2024
|
New Strong Buy Stocks for December 24th
- FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024.
- 12/24/2024
|
NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why
- NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 11/27/2024
|
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024
- WILMINGTON, Del., Nov. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.
- 11/26/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"
- NRx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of NRX-101 documents higher interrater reliability (IRR) on primary endpoint (MADRS depression scale) than previously reported industry standards Positive implications for conduct of future registration trials for NRX-101 and similar medications. Published in the peer reviewed American Journal of Clinical Psychopharmacology WILMINGTON, Del.
- 11/25/2024
|
NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2024 Earnings Conference Call November 18, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Richard Narido - Interim Chief Financial Officer and Treasurer Michael Abrams - Incoming Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital Ed Woo - Ascendiant Vernon Bernardino - H.C.
- 11/18/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer
- Industry veteran with extensive experience in key areas of focus Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities WILMINGTON, Del., Nov. 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it has appointed Michael Abrams as its permanent Chief Financial Officer.
- 11/18/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update
- On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for Accelerated Approval in bipolar depression with suicidality or akathisia by year end 2024 with 2025 PDUFA date forecast. HOPE Therapeutics acquiring Interventional Psychiatry Clinics; key to developing a best-in-class network of care to prevent suicide, continues to expect first revenue by year-end 2024.
- 11/14/2024
|
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024
- WILMINGTON, Del. , Nov. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will reschedule its third quarter and year to date 2024 results conference call to Monday November 18, 2024 at 4:30pm ET, to accommodate any additional corporate news.
- 11/13/2024
|
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024
- WILMINGTON, Del. , Nov. 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter and year to date 2024 financial results after the market closes on Thursday, November 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.
- 11/07/2024
|
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics
- The clinics are located in favorable locations, are revenue generating and EBITDA positive Clinics offer a comprehensive range of mental health services Acquisition is expected to be immediately accretive to revenue and EBITDA for HOPE and NRx MIAMI , Oct. 30, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of its first Interventional Psychiatry Clinics in Florida. These clinics are seen as top performers and will form the Company's foundation for growth in Florida.
- 10/30/2024
|
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
- MIAMI, FL., October 23, 2024 – PRISM MediaWire – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc.
- 10/23/2024
|
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
- MIAMI, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.
- 10/23/2024
|
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
- Clinic to serve as the prototype for HOPE's network of Interventional Psychiatric Clinics Nationally recognized founder to become Chief Medical Innovation Officer of HOPE, in order to implement and evolve the Company's standard of care across the HOPE network Acquisition would be immediately accretive to revenue and EBITDA for HOPE and NRx MIAMI , Oct. 3, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of a premier West Coast Interventional Psychiatric Clinic. Importantly, as a component of the acquisition, the founder of the clinic, a pioneer and nationally recognized leader in the use of advanced treatments for treatment of CNS disorders, has agreed to join HOPE as Chief Medical Innovation Officer (CMIO).
- 10/03/2024
|
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)
- Stability milestone supports submission of FDA New Drug Application by NRx for the use of intravenous ketamine to treat Suicidal Depression Ketamine is currently used off-label for this indication. However, FDA approval is typically required for patients to obtain insurance reimbursement NRX-100 is the first preservative-free formulation of Ketamine, potentially avoiding toxic side effects of preservatives used in current preparations designed for single dose anesthetic use RADNOR, Pa.
- 09/30/2024
|
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
- "How NRx Could Upend the Fight Against Depression and Suicide" RADNOR, Pa. , Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com.
- 09/11/2024
|
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
- MIAMI , Sept. 3, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company") and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a presenting companies at the H.C.
- 09/03/2024
|
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
- $30 million Term Sheet from qualified lender for non-dilutive financing for first clinic acquisitions; anticipated closing within 60 days Executed Non-Binding Term Sheet with initial clinic partners generating annual revenue of over $10 million, with additional partners to be selected under this initial funding agreement Company projects annualized revenues of $100 million through continued acquisition by mid 2025 Additional information to be presented at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024 MIAMI , Aug. 26, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("HOPE," the "Company"), a medical and technology driven company, today announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, the Company has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million.
- 08/26/2024
|
NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Dr. Jonathan Javitt - Founder, Chairman and Chief Scientist Stephen Willard - Chief Executive Officer Richard Narido - Chief Financial Officer and Treasurer Conference Call Participants Ed Woo - Ascendiant Operator Good afternoon, everyone. And welcome to the NRx Pharmaceuticals Incorporated Second Quarter of 2024 Results Conference Call.
- 08/15/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
- Company is now funded for and focused on New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101 Audit of HOPE Therapeutics is now complete, SEC filing of spinout this quarter Key Milestones Secured $10.8 - $16.3 million in convertible-debt funding from an institutional investor; funds targeted to support FDA New Drug Applications for NRX-100 (ketamine) and NRX-101. Replacement funding entails substantial reduction in interest rate, conversion discount, and other financial terms compared to prior debt Retirement of Streeterville debt and settlement of litigation at a substantial discount to litigation claims NRX-100 NDA for suicidal depression based on data from four clinical trials in nearly 1000 participants demonstrating highly significant efficacy compared to placebo, active comparator, and electroshock therapy Ketamine findings have just been confirmed in published 43,000 person cohort study1 Phase 2b/3 trial of NRX-101 in suicidal patients with bipolar depression demonstrated depression efficacy comparable to standard of care and significant reduction of akathisia (P=0.025) and time to sustained remission from suicidality (P=.05).
- 08/14/2024
|
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
- RADNOR, Pa. , Aug. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter and year to date 2024 financial results after the market closes on Wednesday, August 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.
- 08/13/2024
|
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds
- This financing is expected to support 2024 filing of New Drug Applications forNRX-100 (ketamine) and NRX-101 and to support launch of HOPE Therapeutics Streeterville Capital has agreed to a settlement of all claims to be paid from the proceeds of this financing RADNOR, Pa. , Aug. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has obtained up to approximately $16 million in convertible debt financing (the "Financing") from an institutional investor.
- 08/13/2024
|
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)
- FDA response highlights the importance of addressing suicidal depression in adolescents age 9-17 Alignment on initial Pediatric Study Plan (iPSP) is a gating requirement for the upcoming filing of an NRX-100 New Drug Application (NDA) for suicidal depression NRx remains on track to file the NDA for NRX-100 in Q4 2024 with anticipated PDUFA date in Q2 2025 RADNOR, Pa. , July 29, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company, today announced a communication from the US Food and Drug Administration (FDA) providing feedback and alignment on NRx's proposed initial Pediatric Study Plan (iPSP) for NRX-100 (ketamine) in the treatment of suicidal depression.
- 07/29/2024
|
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff
- Petition for a temporary restraining order brought by Streeterville Capital, LLC seeking injunctive relief to prevent spinoff of 49% of HOPE Therapeutics shares to current NRx Shareholders has been denied by Utah arbitrator. Petition by Streeterville Capital, LLC seeking injunctive relief to prevent sales of NRx shares has been denied by Utah arbitrator.
- 07/29/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
- Potential paths to revenue and profitability in 2025 RADNOR, Pa. , July 1, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company posted a new Shareholder Update Letter on its website NRx Shareholder Update and further invites interested parties to subscribe to their email alert service to stay up to date on company's progress here: NRx Email Alerts.
- 07/01/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing
- New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 2024, based on two positive trials 1 2 and Breakthrough Therapy Designation. Potential revenue in 2025 NDA for NRX-100 (IV ketamine) in suicidal depression in advanced preparation for submission in 2024; based on four positive trials 3 4 5 6 and Fast Track Designation.
- 06/28/2024
|
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024
- RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company, today announced that management will participate in the H.C.
- 06/20/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors
- Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology Retired at a rank that is the civilian equivalent of a senior flag officer from the United States Navy RADNOR, Pa. , June 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has added Dr. Dennis McBride to its Board of Directors.
- 06/18/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
- The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating severe depression and suicidality Presenters from 3 open label studies at the ASCP suggested that intravenous ketamine is at least equivalent and may have advantages over intranasal S-ketamine NRx Pharmaceuticals has now reached the 9-month stability point with its ketamine formulation (NRX-100) and has initiated 3 manufacturing lots for future drug release. Nonclinical safety for short term use of NRX-100 has recently been published and submitted to FDA FDA leadership, in public comments at ASCP, focused on the need for nonclinical safety data for intravenous ketamine as a condition of ketamine approval The short-term need for intravenous ketamine as an already-approved, schedule 3 drug, is heightened by recent regulatory decisions that may delay the path of potent, schedule 1 psychedelic drugs that may require more complicated clinical trial designs.
- 06/10/2024
|
NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression
- Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior" NRX-101 demonstrated a similar antidepressant effect (MADRS reduction ~50%) compared to lurasidone, the Standard of Care drug NRX-101 demonstrated a 58% relative reduction in time to sustained remission from suicidality (P=.05) compared to lurasidone NRX-101 demonstrated a 76% reduction in symptoms of akathisia (p=0.03), a side effect linked to suicide, compared to lurasidone This represents the second trial of NRX-101 demonstrating reduction in suicidality and akathisia associated with NRX-101 compared to lurasidone RADNOR, Pa. , May 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical stage pharmaceutical company, today announced presentation of its Phase 2b/3 trial of NRX-101, entitled "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior" at the American Society of Clinical Psychopharmacology (ASCP) in Miami Beach, FL.
- 05/28/2024
|
NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Matthew Duffy - Company's Chief Business Officer Stephen Willard - Chief Executive Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Richard Narido - Chief Financial Officer and Treasurer Conference Call Participants Tim Moore - EF Hutton Ed Woo - Ascendiant Capital Operator Good afternoon, everyone. And welcome to the NRx Pharmaceuticals, Inc. First Quarter of 2024 Results Conference Call [Operator Instructions].
- 05/14/2024
|
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
- 2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional investor for an initial $7.5 million note, subject to common closing requirements, primarily to replace current debt, clearing the path to a Hope Therapeutics share distribution, with provision for funding up to $30 million to fund pipeline opportunities Positive data from a Phase 2b/3 trial of NRX-101 in Treatment Resistant Bipolar Depression (TRBD); trial demonstrated depression efficacy comparable to standard of care and significant reduction of akathisia (P=0.025). Akathisia is a potentially lethal side effect of all serotonin-targeted antidepressants and is associated with suicide.
- 05/14/2024
|
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
- RADNOR, Pa. , May 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will participate in the EF Hutton Annual Global Conference, which will take place on May 15, 2024, at The Plaza Hotel in New York City.
- 05/08/2024
|
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
- RADNOR, Pa. , May 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2024 financial results after the market closes on Tuesday, May 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.
- 05/07/2024
|
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
- Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size .37; P=0.025), using prespecified analytic methodology memorialized in FDA Special Protocol Agreement.
- 05/06/2024
|
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
- NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to lurasidone - never previously shown with an oral antidepressant. Suicidality signal met the study's promising zone criteria and the akathisia signal approached statistical significance (P=0.076) Both NRX-101 and lurasidone, an accepted standard of care in Bipolar Depression, demonstrated approximately 50% reduction in symptoms of depression These data are comparable to previous statistically-significant finding of reduced suicidality and in the published STABIL-B trial and support an approval pathway via a 300-person registrational trial with sustained remission in suicidality as the primary endpoint Company believes that an oral antidepressant that demonstrates reduction in suicidality has potential to become standard of care for treatment of bipolar depression.
- 04/30/2024
|
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
- The latest trading day saw NRx Pharmaceuticals, Inc. (NRXP) settling at $3.14, representing a +0.64% change from its previous close.
- 04/25/2024
|
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
- In the most recent trading session, NRx Pharmaceuticals, Inc. (NRXP) closed at $3.04, indicating a +0.66% shift from the previous trading day.
- 04/19/2024
|
Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?
- NRX Pharmaceuticals (NASDAQ: NRXP ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a proposed public offering for its shares. NRX Pharmaceuticals is selling $2 million worth of NRXP stock for $3.30 per share in this offering.
- 04/18/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
- The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter Four upcoming milestones expected: data from trials in Suicidal Bipolar Depression and Chronic Pain, NDA filing for IV Ketamine and distribution of shares of HOPE Therapeutics to existing shareholders Recent unanticipated achievements related to intravenous ketamine and complicated Urinary Tract Infection/pyelonephritis RADNOR, Pa. , April 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that (the "Company") has received confirmation from Nasdaq that they have demonstrated compliance with the Nasdaq bid price requirement in Listing Rule 5550(a)(2) and has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter.
- 04/18/2024
|
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
- RADNOR, Pa. , April 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of shares of its common stock at a public offering price of $3.30 per share, for aggregate gross proceeds of approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses.
- 04/18/2024
|
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
- RADNOR, Pa. , April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering.
- 04/17/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
- Formulation based on prior patents by NRx founder Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration Company expects Composition of Matter patent protection Company previously executed joint development agreement with US manufacturer of insulin pumps RADNOR, Pa. , April 15, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has developed a novel, proprietary formulation of IV Ketamine for use as HTX-100.
- 04/15/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
- Data transferred for independent statistical analysis Top-line data expected in April 2024 RADNOR, Pa. , April 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101.
- 04/08/2024
|
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Know
- NRx Pharmaceuticals (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 04/04/2024
|
New Strong Buy Stocks for April 4th
- DELL, NRXP, STEP, TCOM and PARAA have been added to the Zacks Rank #1 (Strong Buy) List on April 4, 2023.
- 04/04/2024
|
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
- NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
- 04/01/2024
|
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend -- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. Additions to working capital of $8 million in Q1 2024.
- 04/01/2024
|
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
- Four potential near-term milestones, including data from two clinical trials, an NDA filing and a share dividend RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announces its anticipated financial results for the quarter and year ended December 31, 2023 and provides the following summary of its expected annual report to be filed later today.
- 03/28/2024
|
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
- Common Stock Will Begin Trading on Split-Adjusted Basis on April 2, 2024 RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.
- 03/28/2024
|
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
- RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases.
- 03/21/2024
|
Why Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today?
- NRX Pharmaceuticals (NASDAQ: NRXP ) stock is falling on Tuesday after the clinical-stage pharmaceutical company announced a proposed public offering for its shares. We still don't know the finer details of the public offering.
- 02/27/2024
|
NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco
- The benefits of ketamine are clear, but so are the risks Ketamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more than 1,000 patients NRx to file a New Drug Application for ketamine to treat suicidal depression in 2024 in US and EU RADNOR, Pa. , Jan. 2, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", (NRx), a clinical-stage biopharmaceutical company today announced that it has been selected to give the keynote address entitled "Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks," at the upcoming Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024.
- 01/02/2024
|
Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree
- We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.
- 12/22/2023
|
5 Biotech stocks tapping into unmet mental health treatment needs
- Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giving patients new hope for recovery and the ability to thrive.
- 12/20/2023
|
3 Penny Stocks Under $3 To Watch Right Now
- As an aggressive subset of equities, penny stocks offer patient investors occasional lottery ticket-like returns. However, the market gyrations around news and events also invite risk.
- 12/19/2023
|
NRX Pharmaceuticals, Inc. (NRXP) Q3 2023 Earnings Call Transcript
- NRX Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Stephen Willard - Chief Executive Officer Jonathan Javitt - Founder & Chief Scientist Richard Narido - Chief Financial Officer & Treasurer Conference Call Participants Ed Woo - Ascendiant Capital Operator Thank you for standing by. This is the conference operator.
- 11/14/2023
|
NRx Pharmaceuticals to Present at 8th Annual Dawson James Conference
- RADNOR, Pa. , Oct. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the 8th Annual Dawson James Conference on Thursday, October 12th, 2023, at the Wyndam Grand Jupiter at Harbourside Place, in Jupiter Florida.
- 10/05/2023
|
NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up
- NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.
- 10/03/2023
|
NRx Pharmaceuticals to Present at the Sidoti Virtual Small Cap Conference
- RADNOR, Pa. , Sept. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D.
- 09/18/2023
|
NRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- RADNOR, Pa. , Sept. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D.
- 09/07/2023
|
NRX Pharmaceuticals, Inc. (NRXP) Q2 2023 Earnings Call Transcript
- NRX Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Steve Willard - CEO & Director Jonathan Javitt - Chief Scientist & Director Seth Voorhees - CFO Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Good day and welcome to the NRX Pharmaceuticals Incorporated Second Quarter 2023 Earnings Conference Call. [Operator Instructions].
- 08/14/2023
|
NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023
- RADNOR, Pa. , Aug. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its second quarter 2023 financial results after the market closes on Monday, August 14, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.
- 08/07/2023
|
NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023
- RADNOR, Pa. , June 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update conference call on Monday, June 5, 2023 at 8:30 a.m.
- 06/02/2023
|
All You Need to Know About NRx Pharmaceuticals, Inc. (NRXP) Rating Upgrade to Buy
- NRx Pharmaceuticals, Inc. (NRXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 05/31/2023
|
NRx Pharmaceuticals, Inc. (NRXP) Q4 2022 Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Suzanne Messere - IR Stephen Willard - CEO Seth Van Voorhees - CFO Jonathan Javitt - Chief Scientist Conference Call Participants Jason Kolbert - Dawson James Vernon Bernadino - H.C. Wainwright Ed Woo - Ascendiant Capital Operator Good afternoon and welcome to the NRx Pharmaceuticals Full Year 2022 Results Conference Call.
- 03/30/2023
|
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
- RADNOR, Pa. , March 17, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage CNS biopharmaceutical company, a Delaware Corporation, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Thursday, March 30, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.
- 03/17/2023
|
NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference
- RADNOR, Pa. , Jan. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates ("6th Annual NIF").
- 01/05/2023
|
NRx Pharmaceuticals, Inc. (NRXP) Q3 2022 Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Suzanne Messere - Investor Relations Stephen Willard - Chief Executive Officer Seth Van Voorhees - Chief Financial Officer and Treasurer Jonathan Javitt - Founder and Chief Scientist Conference Call Participants Vernon Bernadino - H.C. Wainwright Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the NRx Pharmaceuticals Third Quarter 2022 Earnings Conference Call.
- 11/14/2022
|
5 Penny Stocks To Buy According To Analysts, Targets Up To 353%
- Analysts say these are penny stocks to buy. Do you agree?
- 11/11/2022
|
NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022
- --Company to Host Conference Call November 14, 2022, at 8:00AM ET--- RADNOR, Pa. , Nov. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022.
- 11/10/2022
|
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference
- Company to Present Corporate Update During Investor Conference, Sept. 14, 2022, at 9:00am ET RADNOR, Pa.
- 09/08/2022
|
NRx Pharmaceuticals, Inc. (NRXP) CEO Stephen Willard on Q2 2022 Results - Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Tom Johnson - Investor Relations Stephen Willard - Chief Executive Officer Seth Van Voorhees - Chief Financial Officer & Treasurer Robert Besthof - Head of Operations & Chief Commercial Officer Conference Call Participants Vernon Bernardino - HC Wainwright Operator Good day, and welcome to the NRx Pharmaceuticals Second Quarter 2022 Conference Call. All participants will be in a listen-only mode.
- 08/15/2022
|
NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022
- --Company to Host Conference Call August 15th, 2022, at 8:30AM ET--- RADNOR, Pa. , Aug. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report second quarter 2022 financial results prior to the market open on August 15, 2022.
- 08/10/2022
|
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond
- Company to Present Corporate and Psychiatry Franchise Update During Webcast, June 27, 2022, at 7:00am ET RADNOR, Pa. , June 23, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other executive leaders will be presenting a virtual update to the company's business via webcast at the H.C.
- 06/23/2022
|
Why Is NRx Pharmaceuticals (NRXP) Stock Down 60% Today?
- Today, investors in NRx Pharmaceuticals and NRXP stock have seen heavy selling pressure as a key trial was stopped due to futility. The post Why Is NRx Pharmaceuticals (NRXP) Stock Down 60% Today?
- 05/26/2022
|
Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?
- Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) determined that the evaluation of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (aviptadil) should cease due to futility. Aviptadil was the sole remaining investigational medicine in.
- 05/26/2022
|
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference
- Company to Present Corporate Update During Investor Webcast, May 24, 2022, at 7:00am ET RADNOR, Pa. , May 19, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other executive leaders will be presenting a virtual update to the company's business via webcast at the H.C.
- 05/19/2022
|
NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q1 2022 Results - Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Robert Besthof – Interim Chief Executive Officer, Head of Operations & Chief Commercial Officer Tom Johnson – Investor Relations Ira Strassberg – Chief Financial Officer and Treasurer Conference Call Participants Operator Greetings and welcome to NRX Pharmaceuticals First Quarter 2022, Earnings Conference Call. At this time, all participants are in listen-only mode.
- 05/16/2022
|
NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022
- --Company to Host Conference Call May 16, 2022, at 8:30AM ET-- RADNOR, Pa. , May 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company today announced that management will report first quarter 2022 financial results prior to the market open on May 16, 2022.
- 05/10/2022
|
NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare Conference
- Company to Present Corporate Update During Investor Webcast, April 14, 2022, at 4:30pm ET RADNOR, Pa. , April 8, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other executive leaders will be presenting updates to the company's business at the 21st Annual Needham Virtual Healthcare Conference.
- 04/08/2022
|
NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q4 2021 Results - Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q4 2021 Results - Earnings Call Transcript
- 03/31/2022
|
NRx Pharma Says I-SPY Study Of Inhaled Zyesami In Critical COVID-19 Stopped
- Quantum Leap Healthcare Collaborative (QLHC) announced that the nebulized form of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (Aviptadil) in the I-SPY COVID Trial of critical patients had been stopped. The I-SPY COVID Trial is a phase 2 trial designed to rapidly.
- 03/31/2022
|
NRx Pharmaceuticals to Report Year-End 2021 Results on March 31, 2022
- --Company to Host Conference Call March 31, 2022, at 8:30AM ET--- RADNOR, Pa. , March 28, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company today announced that management will report year end 2021 financial results prior to the market open on March 31, 2022.
- 03/28/2022
|
NRx Pharmaceuticals: Potential For First In Bipolar Depression Suicidal Ideation Treatment, Along As Covid-19 Play
- NRx Pharmaceuticals: Potential For First In Bipolar Depression Suicidal Ideation Treatment, Along As Covid-19 Play
- 02/23/2022
|
NRx Pharmaceuticals Raises $25M Via Equity To Support Its Pipeline Development
- NRx Pharmaceuticals NRXP has announced the private placement of 7.8 million shares priced at a premium to market under Nasdaq rule, for gross proceeds of $25 million. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.
- 01/31/2022
|
NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments
- NRx Pharmaceuticals (NASDAQ: NRXP) has announced enhancements to its Expanded Access and Right to Try programs. The programs enable patients to receive Zyesami (aviptadil) upon a physician's prescription, with respiratory failure from COVID-19, who have tried all approved medicines, including remdesivir, and who cannot participate in a clinical study.
- 01/18/2022
|
NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights
- NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing dispute over the COVID-19 treatment Zyesami (avaptadil). NRx alleges that Relief has breached a collaboration agreement and falsely asserted worldwide right to Zyesami.
- 01/13/2022
|
3 Reddit Penny Stocks For Your Watch List In January 2022
- Reddit penny stocks to watch this week. The post 3 Reddit Penny Stocks For Your Watch List In January 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/10/2022
|
NRx Pharmaceuticals to Announce New Details for Planned Investigational BriLife™ COVID-19 Vaccine
- RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Prof Jonathan Javitt, MD, MPH, will be presenting updates to the Company's business, including new details regarding late-stage trials of the investigational BriLife™ COVID-19 vaccine at the H.C. Wainwright BioConnect Virtual Conference.
- 01/07/2022
|
NRx Pharmaceutical's Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright BioConnect Virtual Conference
- RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Prof Jonathan Javitt, MD, MPH, will be presenting updates to the Company's business at the H.C. Wainwright BioConnect Virtual Conference.
- 01/07/2022
|
NRXP Stock Alert: The Covid-19 News Lifting NRx Pharmaceuticals Today
- News of a potential Covid-19 treatment breakthrough has NRXP stock rising today. Here's what you need to know about this FDA filing.
- 01/05/2022
|
3 Biotech Stocks That Could Double in 2022
- They're risky. But with the high risk comes the potential for high rewards.
- 01/03/2022
|
NRXP Stock Alert: What Is Going on With NRx Pharmaceuticals Today?
- NRx is seeking to have the FDA grant its coronavirus treatment breakthrough designation, based on new, favorable data on the drug. NRXP stock is climbing on the news.
- 12/29/2021
|
Hot Penny Stocks To Watch Before Today's Opening Bell
- These penny stocks are on the move, early and here's why. The post Hot Penny Stocks To Watch Before Today's Opening Bell appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/29/2021
|
Why NRx Pharmaceuticals Stock Soared Today
- Investors are intrigued by the potential of the drugmaker's experimental coronavirus therapy.
- 11/29/2021
|
4 Top Biotech Stocks To Watch Now
- With all eyes on the pandemic once again, these biotech players could be gaining more exposure.
- 11/29/2021
|
NRx Pharmaceuticals (NRXP) Stock: Why The Price Surged Today
- The stock price of NRx Pharmaceuticals (NASDAQ: NRXP) increased by over 40% pre-market today. This is why it happened.
- 11/29/2021
|
Why Are NRx Pharma's Shares Soaring Premarket?
- NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's (NASDAQ: GILD) remdesivir in the COVID-AIV trial representing approximately 70% of the study population. The analysis indicates a substantial improvement after Zyesami (aviptadil) treatment in patients with critical COVID-19 and Respiratory Failure over existing therapies.
- 11/29/2021
|
NRx Pharma Skyrockets After BriLife COVID-19 Vaccine Data Against Delta Variant
- Israel Institute for Biological Research (IIBR) has posted scientific results from an initial sample of Phase 2 vaccinated patients to assess the BriLife vaccine against the COVID-19 Delta variant. Blood (Sera) from an initial sample of 11 trial participants demonstrated effective neutralizing antibodies against the original "wild-type" virus and was tested for antibodies to the Delta variant.
- 11/26/2021
|
FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate
- Relief Therapeutics Holding SA's (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil. NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.
- 11/24/2021
|
NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q3 2021 Results - Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q3 2021 Results - Earnings Call Transcript
- 11/16/2021
|
NRx Pharmaceutical's Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel Conference
- Conference Begins on November 15, 2021 Conference Begins on November 15, 2021
- 11/12/2021
|
NRx Pharma's COVID-19 Candidate Receives FDA Review For Manufacturing Information
- NRx Pharmaceuticals Inc (NASDAQ: NRXP) has received the FDA's response to NRx's submission of updated manufacturing information for Zyesami (aviptadil). The completion of this review, without the imposition of any clinical hold by the FDA, enables NRx to distribute Zyesami for clinical trials and other future purposes approved in future regulatory actions.
- 11/11/2021
|
Why NRX Pharmaceuticals Stock Is Jumping Today
- The company received good news from the FDA.
- 11/11/2021
|
NRx Pharmaceuticals to Report Third Quarter 2021 Financial and Business Update on Tuesday, November 16, 2021
- --Company to Host Conference Call on Tuesday, November 16, 2021, at 8:30AM ET-- --Company to Host Conference Call on Tuesday, November 16, 2021, at 8:30AM ET--
- 11/09/2021
|
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
- The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing aviptadil in collaboration with Relief Therapeutics Holding SA (OTC: RLFTF).
- 11/05/2021
|
1 Small-Cap Stock With 10X Potential
- This company's coronavirus efforts could pay off big time.
- 10/27/2021
|
2 Biotech Stocks Poised for Jaw-Dropping Growth
- These two tiny drugmakers could make early shareholders wealthy.
- 10/17/2021
|
Why NRx Pharmaceuticals Stock Is Tumbling Today
- The drugmaker is being sued by Relief Therapeutics.
- 10/15/2021
|
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
- GENEVA, SWITZERLAND / ACCESSWIRE / October 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (" NRx "), has issued a press release announcing that the peer-reviewed Journal of Infectious Diseases and Treatment has published positive trial data from a prospective, open label, administratively controlled trial of aviptadil in high comorbidity patients suffering from critical COVID-19 with respiratory failure. According to the press release, the study reported 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment at the Houston Methodist Hospital (P
- 10/15/2021
|
Pharma Stock Rises After Upbeat Covid Treatment Data
- NRx Pharmaceuticals Inc (NASDAQ:NRXP) burst onto the scene today, tacking on 35.3% to trade at $12.77 at last check, following the publication of peer-reviewed results from a controlled trial of NRx's drug, aviptadil.
- 10/14/2021
|
Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday
- New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.
- 10/14/2021
|
Why NRX Pharmaceuticals Stock Is Surging Today
- NRX Pharmaceuticals Inc (NASDAQ: NRXP) is trading significantly higher Thursday after the company announced the Journal of Infectious Diseases and Treatment published trial data of aviptadil in high comorbidity patients suffering from critical COVID-19 with respiratory failure. The study reported 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment at the Houston Methodist Hospital.
- 10/14/2021
|
NRXP Stock: The Critical Covid-19 Trial Results That Have NRx Pharma Rocketing Higher
- NRX Pharmaceuticals (NRXP) stock is surging higher on Thursday thanks to recent results from a clinical trial of its Covid-19 treatment. The post NRXP Stock: The Critical Covid-19 Trial Results That Have NRx Pharma Rocketing Higher appeared first on InvestorPlace.
- 10/14/2021
|
Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure
- RADNOR, Pa., Oct. 14, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of respiratory failure in patients with Critical COVID-19.
- 10/14/2021
|
Are the shares of NRX Pharma making a comeback? A look at the charts
- Shares of NRX Pharmaceuticals Inc. (NASDAQ: NRXP) spiked in price by over 60% on Tuesday due to positive news from the FDA related to their product Zyesami. This could be the return of their shares after a 65% fall over the past 6 months.
- 10/13/2021
|
NRXP Stock: Why It Substantially Increased
- The stock price of NRx Pharmaceuticals Inc (NASDAQ: NRXP) increased by over 61% yesterday. This is why it happened.
- 10/13/2021
|
Why NRX Pharmaceuticals Shares Are Rising
- NRX Pharmaceuticals Inc (NASDAQ: NRXP) shares are trading higher by 54.1% at $10.45 after the company announced progress on the worldwide commercial-scale development of ZYESAMI. The company announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI was submitted to the FDA, containing documentation that confirmed Nephron Pharmaceuticals, Inc. is prepared to supply ZYESAMI on a commercial scale.
- 10/12/2021
|
Why NRx Pharmaceuticals Stock Is Skyrocketing Today
- The company announced progress on two fronts for its experimental COVID-19 drug Zyesami.
- 10/12/2021
|
NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
- RADNOR, Pa., Sept. 29, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health.
- 09/29/2021
|
NRx Pharma's COVID-19 Candidate Shows Improved Survival At One Year
- NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced top-line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 treated with Zyesami. Between June and September 2020, a trial was conducted at a tertiary care hospital involving patients with Critical COVID-19 whose level of comorbidity excluded them from the Phase 2b/3 trial of Zyesami.
- 09/27/2021
|
NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil)
- RADNOR, Pa., Sept. 27, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMI™.
- 09/27/2021
|
IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals
- IQVIA (IQV) and NRx are set to work closely to support activities essential for emergency use authorization of ZYESAMI.
- 09/14/2021
|
Why Are NRx Pharma Shares Moving Higher On Tuesday Premarket?
- Iqvia Holdings Inc (NYSE: IQV) has collaborated with NRx Pharmaceuticals Inc (NASDAQ: NRXP) to provide pharmacovigilance services and medical information in preparation for potential regulatory actions. IQVIA will work closely with NRx to support key activities required for emergency use authorization activation for Zyesami in COVID-19, including the pharmacovigilance and medical information programs.
- 09/14/2021
|
IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment
- RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx) (Nasdaq: NRXP). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to
- 09/13/2021
|
NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
- RADNOR, Pa., Sept. 8, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C.
- 09/08/2021
|
NRx Pharma Stock Is Moving Higher On COVID-19 Candidate Data
- NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced an additional finding from its Phase 2b/3 trial investigating Zyesami (aviptadil) for critically ill COVID-19 patients with acute respiratory failure. Previously announced results have focused on survival and recovery from respiratory failure at 60 days and Zyesami's role in preventing the rise in the inflammatory cytokine IL-6 (cytokine storm).
- 08/30/2021
|
NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
- RADNOR, Pa., Aug. 30, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory Failure due to Critical COVID-19.
- 08/30/2021
|
NRx Pharma, Cardinal Health Ink Zyesami Distribution Pact
- NRx Pharmaceuticals Inc (NASDAQ: NRXP) has signed an agreement with Cardinal Health Inc (NYSE: CAH) to provide third-party logistics and distribution of Zyesami upon the potential FDA Emergency Use Authorization (EUA) approval. In May, NRx applied for EUA to the FDA for Zyesami (aviptadil) for critical COVID-19 patients with respiratory failure.
- 08/26/2021
|
NRXP Stock: Over 16% Increase Explanation
- The stock price of NRx Pharmaceuticals (Nasdaq: NRXP) increased by over 16% during intraday trading. This is why it happened.
- 08/26/2021
|
NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies
- RADNOR, Pa., Aug. 26, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug Administration (FDA).
- 08/26/2021
|
NRx Pharmaceuticals Announces Closing of $30 Million Private Placement
- RADNOR, Pa., Aug. 24, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock.
- 08/24/2021
|
Why NRx Pharmaceuticals Stock Vaulted Higher Today
- Investors cheered reports in Israel that COVID-19 vaccine candidate BriLife appears to provide protection for at least six months after a second dose.
- 08/23/2021
|
Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary
- RADNOR, Pa., Aug. 23, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who received the highest dose vaccine were notified by local health authorities they did not need a third, booster dose of the vaccine as their protection remained high, six months after getting a second dose.
- 08/23/2021
|
NRx Pharma Stock Under Pressure On Equity Raise Of $30M
- NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock shed yesterday's gains after announcing a private placement of 2.72 million shares. The purchase price for one share of common stock and one investment option is $11.00.
- 08/19/2021
|
Why NRx Pharmaceuticals Stock Is Sinking Today
- The company announced a price placement for more than 2.7 million new shares and stock options.
- 08/19/2021
|
NRx Pharmaceuticals Announces $30 Million Private Placement
- RADNOR, Pa., Aug. 19, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 2,727,273 shares of common stock in a private placement.
- 08/19/2021
|
Why NRx Pharmaceuticals Stock Jumped 11.8% Today
- The company provided a positive update from a clinical study evaluating its COVID-19 therapy Zyesami.
- 08/18/2021
|
Why NRx Pharma Stock Is Trading Higher In Mid Day Session Wednesday?
- Rx Pharmaceuticals Inc (NASDAQ: NRXP) shares are up around 25% during mid-day session on mild volume, in reaction to safety update on Zyesami (aviptadil) ACTIV-3 Critical Care Phase 3 study in COVID-19 patients. The NIH-sponsored trial's Data Safety Monitoring Board found no new safety concerns and recommended continued enrollment.
- 08/18/2021
|
NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19
- RADNOR, Pa., Aug. 18, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.
- 08/18/2021
|
NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q2 2021 Results - Earnings Call Transcript
- NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q2 2021 Results - Earnings Call Transcript
- 08/17/2021
|
NRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021
- --Company to Host Conference Call August 17, 2021 at 8:30AM ET-- RADNOR, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second quarter 2021 financial results after the market close on August 16, 2021. The company will host a conference call and webcast on August 17, 2021, 8:30 AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Analysts and investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company's investor relations representative at jmullaly@lifesciadvisors.com.
- 08/11/2021
|
NRx Pharma Starts Mid-Stage COVID-19 Vaccine Trial In Nation of Georgia
- NRx Pharmaceuticals Inc (NASDAQ: NRXP) has initiated a phase 2b dose-confirmatory trial of the BriLife vaccine against COVID-19 in the Nation of Georgia. The vaccine is developed by the Israel Institute for Biological Research (IIBR).
- 08/09/2021
|
NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia
- RADNOR, Pa., Aug. 9, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against COVID-19 in the Nation of Georgia.
- 08/09/2021
|
NRx Pharma Stock Gains On Emergency Use Nod For Zyesami To Treat COVID-19 Patients In Nation Of Georgia
- The Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for NRx Pharmaceuticals Inc's (NASDAQ: NRXP) intravenous Zyesami (aviptadil) to treat critical COVID-19 patients. The company says that the first doses will arrive in the Nation of Georgia within 24 hours.
- 07/27/2021
|
NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia
- RADNOR, Pa., July 27, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous ZYESAMI™ (aviptadil) for the treatment of Critical COVID-19.
- 07/27/2021
|
NRX Pharmaceuticals Climbs Higher After FDA News, Could See A Breakout Soon
- NRX Pharmaceuticals Inc. (NASDAQ: NRXP) shares rallied higher Friday on continued momentum after the company announced the first successful commercial formulation for Zyesami. The stock was trending on social media sites such as StockTwits Friday.
- 07/23/2021
|
NRXP Stock Increases Over 25% Pre-Market: Why It Happened
- The stock price of NRX Pharmaceuticals Inc (NASDAQ: NRXP) increased by over 25% pre-market. This is why it happened.
- 07/23/2021
|
Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?
- Extending yesterday's gain, NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock is up more than 26% during the premarket trading on Friday. NRx's stock opened Thursday up nearly 14% at $11.51 per share after closing Wednesday at $10.11 per share.
- 07/23/2021
|
NRXP Stock Increased 42.86% After Hours: Why It Happened
- The stock price of NRX Pharmaceuticals Inc (NASDAQ: NRXP) increased by 42.86% after hours. This is why it happened.
- 07/23/2021
|
NRXP Stock: This Covid-19 Treatment Could Prime NRx Pharmaceuticals for Big Gains
- NRXP stock came to investors' attention last year with its Covid-19 treatment. Now, it's looking like a great play as it eyes up EUA.
- 07/22/2021
|
NRXP Stock Increased Over 80% Intraday: Why It Happened
- The stock price of NRx Pharmaceuticals Inc (NASDAQ: NRXP) increased by over 80% during intraday trading. This is why it happened.
- 07/22/2021
|
Why NRx Pharmaceuticals Stock Is Soaring Today
- The company achieved two breakthroughs related to the formulation and manufacturing of Zyesami, its experimental COVID-19 drug.
- 07/22/2021
|
NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval
- RADNOR, Pa., July 22, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has validated the first commercial formulation of ZYESAMI™ (aviptadil) for intravenous use, allowing for high volume manufacture, with an anticipated one year or greater stability, under appropriate storage conditions.
- 07/22/2021
|
NRXP Stock: The ‘Cykotine Storm' Drug News Sending NRx Pharma Shares Soaring
- Shares of NRXP stock are taking off on Monday after the pharmaceutical company reported positive results regarding its Zyesami trial. The post NRXP Stock: The ‘Cykotine Storm' Drug News Sending NRx Pharma Shares Soaring appeared first on InvestorPlace.
- 07/19/2021
|
Why NRx Pharmaceuticals Stock Is Skyrocketing Today
- The company reported promising data for its experimental COVID-19 drug Zyesami.
- 07/19/2021
|
Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
- Penny Stocks & Small Caps Jump As Biotech Industry Names Kick Into High Gear The post Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/19/2021
|
NRXP Stock Increases Over 30% Intraday: Why It Happened
- The stock price of NRX Pharmaceuticals Inc (NASDAQ: NRXP) increased by over 30% during intraday trading. This is why it happened.
- 07/19/2021
|
NRx Pharma Stock Surges As Its COVID-19 Candidate Shows Evidence To Prevent "Cytokine Storm"
- NRx Pharmaceuticals (NASDAQ: NRXP) identifies a statistically significant effect of Zyesami (aviptadil) in preventing the sharp rise in cytokines, commonly associated with mortality in patients with COVID-19. Data will be presented at the Disease Control and Prevention Summit on July 21 at 10:10 E.T.
- 07/19/2021
|
NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19
- RADNOR, Pa., July 19, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), will present data at the Disease Control and Prevention Summit on July 21, 2021 at 10:10 EST, via the following link: https://www.terrapinn.com/template/live/landing/a0A4G00001ZmpzpUAB/10433?utm_source=&utm_medium=landing-page&utm_campaign=-referral&utm_term=referral-marketing&utm_content=PA03744357 NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19 The presentation identifies a statistically significant effect of ZYESAMI™ (aviptadil) in preventing the sharp rise in cytokines, commonly associated with mortality in patients with COVID-19.
- 07/19/2021
|
NRx Pharma Starts Treating Patients With Inhaled Aviptadil In Collaborative COVID-19 Trial
- NRx Pharmaceuticals Inc (NASDAQ: NRXP) and Quantum Leap Healthcare Collaborative have begun treating patients with inhaled Zyesami (Aviptadil) in the I-SPY COVID Trial. The I-SPY COVID Trial utilizes Quantum Leap's adaptive platform trial design methodology, which focuses on the efficient assessment of multiple investigational agents simultaneously.
- 07/12/2021
|
NRx Pharmaceuticals and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ (Aviptadil) in the I-SPY COVID Trial
- SAN FRANCISCO and RADNOR, Pa., July 12, 2021 /PRNewswire/ -- NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) have begun treating patients with inhaled ZYESAMIÔ (Aviptadil), in the I-SPY COVID Trial (NCT04488081), a phase 2 adaptive platform trial aimed at improving treatment for severely and critically ill COVID-19 patients.
- 07/12/2021
|
NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia
- RADNOR, Pa., July 6, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage biopharmaceutical company, today announced it is initiating clinical training of Nation of Georgia (Georgia) ICU physicians, in the use of intravenous ZYESAMI™ (Aviptadil- acetate) for emergency use in patients suffering with Critical COVID-19, and inhaled ZYESAMI™ for use in phase 2/3 clinical trials, for patients suffering with COVID-19.
- 07/06/2021
|
NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Protocol
- RADNOR, Pa., June 15, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage pharmaceutical company, today announced positive data from its ZYESAMI™ (Aviptadil) Expanded Access Protocol (EAP).
- 06/15/2021
|
NRx Pharmaceuticals Names General H.R. McMaster to Company's Board of Directors
- RADNOR, Pa., May 27, 2021 /PRNewswire/ -- Today, NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced the election of The Honorable Herbert Raymond "H.R.
- 05/27/2021
|
NRx Pharmaceuticals to Lead Development of COVID-19 Medicines and Vaccines in Central Europe and the Caucasus Region in Collaboration with the Lugar Institute and Cromos Pharma
- RADNOR, Pa., May 26, 2021 /PRNewswire/ -- Today, NRx Pharmaceuticals, Inc., (Nasdaq:NRXP) (NRx) through its Georgia subsidiary, announced that it has signed a master services agreement with Cromos Pharma, LLC, headquartered in Longview, Washington, to conduct phase 3 clinical trials of COVID-19 related drugs and vaccines in Central Europe and the Caucasus Region.
- 05/26/2021
|
